RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:come on 25 cents otc
Thanks for the comments and input. There really isn't much in common with SDI, not to mention that they just did a 25-1 reverse split which shot up their SP. The only commonality between them is they have cartridges to clean the blood. SDI is strickly going after sepsis they as of now are going in a more general path. They are not even at Phase I trial yet.
When I made my comments was more reffering to the partnership deals they have for their products (universities, DoD other branches of government) to finance the research, SDI on the other hand is going it alone and staying focussed on one area unlike them who are trying a cartiridge for everything and, anything they do is immediately released whether relevant or not.
My opinion both still have potential just depends who grabs some big pharma's eyes. I believe the major reason they get more exposure is they are US based but that can change as more info tricklees out.
Don't advocate one better than the other, just two different business models. But this is a SDI board so I will refrain for posting another company here.